<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0409234098
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LAYAL Syrup
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOCETIRIZINE DIHYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Syrup
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R06AE09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Levocetirizine dihydrochloride is the active ingredient of LAYAL. LAYAL is an antiallergic medication.</p><p>For the treatment of signs of illness (symptoms) associated with:</p><p>&bull; allergic rhinitis (including persistent allergic rhinitis).</p><p>&bull; nettle rash (urticaria).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Talk to your doctor or pharmacist before taking LAYAL.</p><p>If you are likely to be unable to empty your bladder (with conditions such as spinal cord injury or enlarged prostate), please ask your doctor for advice.</p><p>If you suffer from epilepsy or are at risk of convulsions, please ask your doctor for advice as use of LAYAL may cause seizure aggravation.</p><p>If you are scheduled for allergy testing, ask your doctor if you should stop taking LAYAL for several days before testing. This medicine may affect your allergy test results.</p><p>Do not take LAYAL:</p><p>&bull; if you are allergic to levocetirizine dihydrochloride, to cetirizine, to hydroxyzine or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull; if you have a severe impairment of kidney function (severe renal failure with creatinine clearance below 10 ml/min).</p><p>Take special care with LAYAL:</p><p>The use of LAYAL is not recommended for infants and children under 2 years.</p><p>Taking other medicines:</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>Taking LAYAL with food and drink:</p><p>Caution is advised if LAYAL is taken at the same time as alcohol or other agents acting on the brain. In sensitive patients, taking Cetirizine or Levocetirizine with alcohol or other medicines that act on the brain may affect alertness and impairment of performance.</p><p>Pregnancy and breast-feeding:</p><p>Tell your doctor if you are pregnant, trying to get pregnant or breastfeeding.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving and using machines:</p><p>Some patients being treated with LAYAL may experience somnolence/ drowsiness, tiredness and exhaustion. Use caution when driving or operating machinery until you know how this medicine affects you. However, special tests have revealed no impairment of mental alertness, the ability to react or the ability to drive in healthy test persons after taking Levocetirizine in the recommended dosage.</p><p>Important information about some of the ingredients of LAYAL.</p><p>Methyl paraben and propyl paraben may cause allergic reactions (possibly delayed), such as headache, stomach upset, and diarrhoea.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take LAYAL exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Use in children:</p><p>&bull; Adults and children from the age of 6 years: 10 ml solution once daily.</p><p>&bull; Children from the age of 2 to 6 years: 2.5 ml solution twice daily.</p><p>The administration of LAYAL to infants and toddlers aged less than 2 years is not recommended.</p><p>Special dosage instructions for specific populations:&nbsp;</p><p>Renal and hepatic impairment</p><p>&bull; Patients with impaired kidney function may be given a lower dose according to the severity of their kidney disease, and in children the dose will also be chosen on the basis of body weight; the dose will be determined by your doctor.</p><p>&bull; Patients who have severe impairment of kidney function must not take LAYAL.</p><p>&bull; Patients who only have impaired liver function should take the usual prescribed dose.</p><p>&bull; Patients who have both impaired liver and kidney function may be given a lower dose depending on the severity of the kidney disease, and in children the dose will also be chosen on the basis of body weight; the dose will be determined by your doctor.</p><p>Elderly patients aged 65 years and above</p><p>&bull; No adaptation of the dose is necessary in elderly patients, provided their renal function is normal.</p><p>How and when should you take LAYAL?</p><p>For oral use only.</p><p>The solution can be taken undiluted or diluted in a glass of water.</p><p>LAYAL may be taken with or without food.</p><p>How long should you take LAYAL?</p><p>The duration of use depends on the type, duration and course of your complaints and is determined by your physician.</p><p>If you take more LAYAL than you should:</p><p>If you take more LAYAL than you should, somnolence can occur in adults. Children may initially show excitation and restlessness followed by somnolence.</p><p>If you think you have taken an overdose of LAYAL, please tell your doctor who will then decide what action should be taken.</p><p>If you forget to take LAYAL:</p><p>If you forget to take LAYAL, or if you take a dose lower than that prescribed by your doctor, do not take a double dose for a forgotten one. Proceed with administration taking the next dose in time.</p><p>If you stop taking LAYAL:</p><p>Stopping treatment should have no negative effects. However, rarely pruritus (intense itching) may occur if you stop taking LAYAL, even if those symptoms were not present before treatment initiation. The symptoms may resolve spontaneously. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should resolve when the treatment is restarted.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, LAYAL can cause side effects, although not everybody gets them.</p><p>Commonly (1% to 10 %), mainly mild to moderate side effects such as dry mouth, headache, tiredness and somnolence/drowsiness have been reported.</p><p>Uncommon (0.1 % to 1 %), side effects such as exhaustion and abdominal pain have been observed.</p><p>Not known, frequency cannot be estimated from the available data</p><p>Other side effects such as palpitations, increased heart rate, fits, pins and needles, dizziness, syncope, tremor, dysgeusia (distortion of the sense of taste), sensation of rotation or movement, visual disturbances, blurred vision, oculogyration (eyes having uncontrolled circular movements), painful or difficult urination, inability to completely empty the bladder, oedema, pruritus (itchiness), rash, urticaria (swelling, redness and itchiness of the skin), skin eruption, shortness of breath, weight increase, muscular pain, joint pain, aggressive or agitated behaviour, hallucination, depression, insomnia, recurring thoughts of or preoccupation with suicide, nightmare, hepatitis, abnormal liver function, vomiting, increased appetite, nausea and diarrhoea have also been reported. Pruritus (intense itching) upon discontiunation.</p><p>Methyl paraben and propyl paraben may cause allergic reactions (possibly delayed).</p><p>At the first signs of a hypersensitivity reaction, stop taking LAYAL and tell your doctor. Hypersensitivity reaction symptoms may include: swelling of the mouth, tongue, face and/or throat, breathing or swallowing difficulties (chest tightness or wheezing), hives, sudden fall in blood pressure leading to collapse or shock, which may be fatal.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.</p><p>&bull; Do not use LAYAL after the expiry date which is stated on the</p><p>label and carton.</p><p>&bull; This medicinal product does not require any special storage</p><p>Conditions.</p><p>&bull; Do not use LAYAL after the bottle has been opened for more than 1 month.</p><p>&bull; Do not use if cap seal is broken.</p><p>&bull; Store Below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>5 ml of syrup contains 2.5 mg Levocetirizine dihydrochloride.</p><p>The other ingredients are: Sorbitol Liquid 70 %, Glycerol, Propylene Glycol, Methyl Paraben, Propyl Paraben, Sodium Acetate, Peach Flavor and Purified Water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The syrup is a clear and colorless solution presented in a 100 ml bottle. The peach flavor taste is obtained through the addition of small amounts of a flavouring agent. The bottle of solution is provided in a card box containing also a patient information leaflet.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jordan Sweden Medical and Sterilization Company (Joswe-medical)</p><p>P.O. Box 851831 Amman 11185 Jordan</p><p>E-mail: joswe@go.com.jo</p><p>www.joswe.com</p><p>Tel: +962 6 5859765, +962 6 5728327</p><p>Fax: +962 6 5814526, +962 6 5728326</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved on 12/2019; Revision number R1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ليفوسيتيريزين دايهيدروكلورايد هي المادة الفعالة في ليال. ليال هو دواء مضاد الحساسية.</p><p dir="RTL">و أيضا لعلاج علامات المرض (الأعراض) المرتبطة ب :</p><p dir="RTL">&bull; التهاب الأنف التحسسي (بما في ذلك التهاب الأنف التحسسي الدائم).</p><p dir="RTL">&bull; طفح القراص (الشرى).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحدث مع الطبيب أو الصيدلاني قبل تناول ليال.</p><p dir="RTL">اذا لم تكن لديك القدرة على تفريغ المثانة (يرافقها حالات مثل اصابة في الحبل الشوكي أو تضخم البروستات)، يرجى طلب المشورة من الطبيب.</p><p dir="RTL">إذا كنت تعاني من الصرع أو كنت عرضة لخطر التشنجات، يرجى طلب المشورة من الطبيب لأن استخدام ليال من الممكن أن يتسبب في تفاقم النوبات.</p><p dir="RTL">إذا كان من المقرر لك إجراء اختبار الحساسية، اسأل الطبيب عما إذا كان يجب عليك التوقف عن تناول ليال لعدة أيام قبل الاختبار. لأنه من الممكن أن يؤثر هذا الدواء على نتائج اختبار الحساسية.</p><p dir="RTL">لا تتناول ليال:</p><p dir="RTL">إذا كنت تعاني من حساسية ضد ليفوسيتيريزين دايهايدروكلورايد، أو سيتيريزين، أو هيدروكسيزين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">إذا كنت تعاني من الفشل الكلوي الشديد (تصفية الكرياتنين &lt; ١٠مل/ دقيقة)</p><p dir="RTL">التحذيرات و الاحتياطات:</p><p dir="RTL">لا ينصح باستخدام ليال للرضع والأطفال من هم تحت عمر السنتين.</p><p dir="RTL">تناول أدوية أخرى:</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أو قد أخذت مؤخرًا أية أدوية، بما في ذلك الأدوية التي حصلت عليها من دون وصفة طبية.</p><p dir="RTL">تناول ليال مع الطعام أو الشراب:</p><p dir="RTL">يجب توخي الحذر عند تناول ليال بالتزامن مع الكحول أو غيرها من العوامل المؤثرة على الدماغ. في المرضى الأكثر تأثراً، فإن تناول سيتيريزين أو ليفوسيتيريزين مع الكحول أو أدوية أخرى تؤثر على العقل قد تؤثر على الوعي وضعف الأداء.</p><p dir="RTL">الحمل والإرضاع:</p><p dir="RTL">اسألي طبيبك إذا كنت حاملا أو&nbsp; تخططين للإنجاب أو تقومين بالرضاعة الطبيعية.</p><p dir="RTL">اسألي طبيبك أو الصيدلي للحصول على المشورة قبل استخدام أي دواء.</p><p dir="RTL">القيادة وتشغيل الآلات:</p><p dir="RTL">من الممكن أن يصاب بعض المرضى الذين يتلقون علاج ليال بالدوخة/ النعاس، التعب أو الإرهاق. توخى الحذر عند قيادة السيارة أو تشغيل الآلات حتى تعرف كيف يؤثر عليك هذا الدواء.&nbsp; ومع ذلك فقد كشفت فحوصات خاصة على الأشخاص الأصحاء عدم اختلال اليقظة العقلية، القدرة على التفاعل أو القدرة على القيادة بعد تناول ليفوسيتيريزين حسب الجرعة المقررة.</p><p dir="RTL">معلومات هامة عن بعض مكونات ليال:</p><p dir="RTL">ميثيل بارابين و بروبيل بارابين قد يسببا الحساسية مثل الصداع واضطرابات المعدة والإسهال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول ليال دائما كما أخبرك الطبيب، تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">الاستخدام من قبل الأطفال:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&bull; البالغين والأطفال من عمر 6 سنوات: 10 مل شراب مرة واحدة يومياً.</p><p dir="RTL">&bull; الأطفال من عمر 2 إلى 6 سنوات: 2.5 مل شراب مرتين يومياً.</p><p dir="RTL">لا ينصح باستخدام ليال&nbsp; للرضع والأطفال من هم دون السنتين.</p><p dir="RTL">التعليمات الخاصة لجرعة فئات معينة:</p><p dir="RTL">قصور في الكبد والكلى:</p><p dir="RTL">&bull; المرضى المصابون بقصور وظائف الكلى يمكن إعطاؤهم جرعة أقل وذلك حسب شدة مرض الكلى لديهم، وللأطفال يتم تحديد الجرعة حسب وزن الجسم، كما يحددها الطبيب.</p><p dir="RTL">&bull; المرضى المصابون بقصور وظائف الكلى الحاد فإنه لا يجب عليهم تناول ليال.</p><p dir="RTL">&bull; المرضى المصابون فقط بقصور وظائف الكبد فإنه يجب عليهم تناول الجرعة كما هي موصوفة.</p><p dir="RTL">&bull; المرضى المصابين بقصور وظائف الكبد وقصور وظائف الكلى يمكن إعطاؤهم جرعة أقل اعتمادا على شدة مرض الكلى لديهم، وللأطفال يتم تحديد الجرعة حسب وزن الجسم، وكما يحددها الطبيب.</p><p dir="RTL">المرضى كبار السن الذين تتراوح أعمارهم بين 65 سنة وما فوق:</p><p dir="RTL">&bull; ليس من الضروري إجراء أي تعديل على الجرعة الخاصة بكبار السن طالما وظائف الكلى لديهم طبيعية.</p><p dir="RTL">كيف ومتى يجب عليك أن تتناول ليال:</p><p dir="RTL">للاستخدام عن طريق الفم فقط.</p><p dir="RTL">الشراب يمكن أن يؤخذ غير مخفف أو مخفف في كوب من الماء.</p><p dir="RTL">يمكن تناول ليال مع أو بدون الطعام.</p><p dir="RTL">كم من الوقت يجب أن تأخذ ليال:</p><p dir="RTL">تعتمد مدة الاستخدام على نوع و مدة وطبيعة شكواك من المرض وتحدد المدة بناء على تعليمات الطبيب.</p><p dir="RTL">إذا كنت قد تناولت ليال أكثر مما يجب:</p><p dir="RTL">إذا تناولت ليال أكثر مما يجب، فمن الممكن أن يصاب البالغين بالنعاس. و قد تظهر على الأطفال بداية حالة من الهيجان والأرق ومن ثم النعاس.</p><p dir="RTL">إذا كنت تعتقد بأنك قد تناولت جرعة مفرطة من ليال، يرجى إخبار طبيبك الذي سوف يقرر ما هي الإجراءات التي ينبغي اتخاذها.</p><p dir="RTL">إذا كنت قد نسيت أن تأخذ ليال:</p><p dir="RTL">إذا نسيت أن تتناول ليال، أو في حال تناولت جرعة أقل مما وصف الطبيب لك، لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة. تناول الجرعة التالية في نفس الوقت المحدد لها.</p><p dir="RTL">إذا توقفت عن تناول ليال:</p><p dir="RTL">وقف العلاج ليس له تأثيرات سلبية. ومع ذلك، نادراً ما قد تصاب بحكة (الحكة الشديدة) إذا توقفت عن تناول ليال، حتى لو لم تكن تلك الأعراض موجودة قبل بدء العلاج. قد تزول هذه الأعراض تلقائيًا. ولكن في بعض الحالات، قد تكون الأعراض شديدة وقد تتطلب إعادة العلاج. يجب أن تزول هذه الأعراض عند إعادة العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية استفسارات حول هذا المنتج، استشر الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه كشأن جميع الأدوية، ليال يمكن أن يسبب آثار جانبية، مع أنها قد لا تحدث لجميع المرضى.</p><p dir="RTL">عادة (1 % - 10%) من التأثيرات الجانبية التي تم تسجيلها بشكل رئيسي بمعدل خفيف إلى متوسط مثل جفاف الفم&nbsp; والصداع والتعب والنعاس.</p><p dir="RTL">من التأثيرات الجانبية غير الشائعة (0,1% - 1%) التي تمت ملاحظتها&nbsp; الإرهاق وآلام البطن.</p><p dir="RTL">غير معروفة، لا يمكن تقدير تكرار حدوثها من البيانات المتاحة.</p><p dir="RTL">الآثار الجانبية الأخرى مثل الخفقان، زيادة معدل ضربات القلب، النوبات، وخز، الدوخة، الإغماء، الارتعاش، عسر الهضم (تشويه الإحساس بالذوق)، الإحساس بالدوران أو الحركة، الاضطرابات البصرية، عدم وضوح الرؤية، تنظير العين (العيون التي تعاني من حركات دائرية لا إرادية)، صعوبة التبول أو التبول المؤلم، عدم القدرة على إفراغ المثانة تماما، وذمة، الحكة، طفح جلدي، الشرى (تورم ، احمرار وحكة في الجلد)، تهيج الجلد، ضيق نفس، زيادة الوزن، ألم في العضلات، ألم في المفاصل،&nbsp; كما تم الإبلاغ عن السلوك العدواني أو المهيج، والهلوسة، الاكتئاب، الأرق ، والتفكير المتكرر بالانتحار، كوابيس، التهاب الكبد، وظائف الكبد غير الطبيعية، التقيؤ، زيادة الشهية، غثيان، إسهال. حكة (حكة شديدة) عند توقف العلاج.</p><p dir="RTL">ميثيل بارابين و بروبيل بارابين من الممكن أن يسببا الحساسية.</p><p dir="RTL">عند أول ظهور لأعراض الإصابة&nbsp; بردود&nbsp; أفعال فرط الحساسية، توقف عن تناول ليال و أخبر طبيبك فورا. قد تشمل أعراض ردود أفعال فرط الحساسية: تورم الفم أو اللسان أو الوجه و/أو الحلق وصعوبة في التنفس أو البلع (ضيق الصدر أو الصفير) وانخفاض مفاجئ في ضغط الدم والذي قد يؤدي إلى الانهيار أو الصدمة التي من الممكن أن تكون خطيرة.</p><p dir="RTL">إذا كان أي من الآثار الجانبية خطير، أو إذا لاحظت أي آثار جانبية غير مذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يحفظ بعيدا عن متناول الأطفال.</p><p dir="RTL">&bull; لا تستخدم ليال بعد إنتهاء فترة الصلاحية المذكورة على اللاصق الداخلي والعبوة الخارجية.</p><p dir="RTL">&bull; لا يحتاج هذا المنتج الطبي إلى ظروف تخزين خاصة.</p><p dir="RTL">&bull; لا تستخدم ليال بعد فتح الزجاجة لأكثر من شهر.</p><p dir="RTL">&bull; لا تستخدم العبوة إذا كانت حلقة الغطاء مكسورة.</p><p dir="RTL">&bull; يحفظ في درجة حرارة أقل من 30 درجة مئوية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">5 مل من الشراب تحتوي 2.5 ملغم ليفوسيتيريزين دايهيدروكلورايد.</p><p dir="RTL">المواد الأخرى: سوربيتول 70%، جليسيرول، بروبلين جلايكول، ميثيل بارابين، بروبيل بارابين، أسيتات الصوديوم، نكهة المشمش، ماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ليال هو شراب صافي و لا لون له، معبأ في زجاجة سعتها 100مل. يتم الحصول على نكهة المشمش من خلال إضافة كمية قليلة من المادة المنكهة.</p><p>يتم توفير الدواء في عبوة كرتونية تحتوي على زجاجة الشراب و نشرة معلومات المريض.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة الأردنية السويدية للمنتجات الطبية و التعقيم.</p><p dir="RTL">ص.ب 851831&nbsp; عمان 11185&nbsp; الأردن</p><p dir="RTL">البريد الالكتروني:joswe@go.com.jo</p><p dir="RTL">www.joswe.com</p><p dir="RTL">هاتف:+962 6 5859765, +962 6 5728327</p><p dir="RTL">فاكس:+962 6 5814526, +962 6 5728326</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت المراجعة هذه النشرة في 12/2019؛ رقم المراجعة R1 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Layal Syrup 2.5 mg/5ml 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Layal syrup: each 5 ml containing 2.5mg Levocetirizine dihydrochloride.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Syrup
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and urticaria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>4.2.1 Posology</strong></p><p>Instruction for use</p><p>A dosing oral syringe is included in the package. The appropriate volume of oral solution should be measured with the oral syringe, and poured in a spoon or in a glass of water. The oral solution must be taken orally immediately after dilution, and may be taken with or without food.</p><p>Adults and adolescents 12 years and above:</p><p>The daily recommended dose is 5 mg (10 ml of solution).</p><p>Elderly:</p><p>Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see Patients with renal impairment below).</p><p>Children aged 6 to 12 years:</p><p>The daily recommended dose is 5 mg (10 ml of solution).</p><p>Children aged 2 to 6 years:</p><p>The daily recommended dose is 2.5 mg to be administered in 2 intakes of 1.25 mg (2.5 ml of solution twice daily).</p><p>Even if some clinical data are available in children aged 6 months to 12 years (see section 4.8, 5.1 and 5.2), these data are not sufficient to support the administration of Levocetirizine to infants and toddlers aged less than 2 years. (see also section 4.4).</p><p>Adult patients with renal impairment:</p><p>The dosing intervals must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula:</p><p>CL<sub>cr</sub> = <u>[140 - age (years)] x weight (kg)&nbsp;</u> (x 0.85 for women)</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;72 x serum creatinine (mg/dl)</p><p>Dosing Adjustments for Patients with Impaired Renal Function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><tbody><tr><td style="vertical-align:top"><p>Group</p></td><td style="vertical-align:top"><p>Creatinine clearance (ml/min)</p></td><td style="vertical-align:top"><p>Dosage and frequency</p></td></tr><tr><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&ge;80</p></td><td style="vertical-align:top"><p>5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50 &ndash; 79</p></td><td style="vertical-align:top"><p>5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30 &ndash; 49</p></td><td style="vertical-align:top"><p>5 mg once every 2 days</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>5 mg once every 3 days</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease - Patients undergoing dialysis</p></td><td style="vertical-align:top"><p>&lt; 10-</p></td><td style="vertical-align:top"><p>Contra-indicated</p></td></tr></tbody></table><p>Paediatric patients suffering from renal impairment:</p><p>The dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and his body weight. There are no specific data for children with renal impairment.</p><p>Patients with hepatic impairment:</p><p>No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of the dose is recommended (see Patients with renal impairment above).</p><p>Duration of use:</p><p>Intermittent allergic rhinitis (symptoms &lt;4days/week or during less than 4 weeks) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear. In case of persistent allergic rhinitis (symptoms &gt;4days/week and during more than 4 weeks), continuous therapy can be proposed to the patient during the period of exposure to allergens. Clinical experience with 5 mg Levocetirizine as a film-coated tablet formulation is currently available for a 6-month treatment period. For chronic urticaria and chronic allergic rhinitis, up to one year&#39;s clinical experience is available for the racemate</p><p><strong>4.2.2 Method of administration </strong></p><p>&nbsp; Oral route.</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to Levocetirizine, to any piperazine derivatives, to methyl parahydroxybenzoate, to propyl parahydroxybenzoate, or to any other excipients. 
Severe renal impairment at less than 10 ml/min creatinine clearance

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Precaution is recommended with intake of alcohol (see Interactions).</p><p>The presence of methyl parahydroxybenzoate and propyl parahydroxybenzoate may cause allergic reactions (possibly delayed).</p><p>Xyzal contains maltitol: Patients with rare hereditary problems of fructose intolerance should not take this medicine.</p><p>Even if some clinical data are available in children aged 6 months to 12 years (see section 4.8, 5.1 and 5.2), these data are not sufficient to support the administration of levocetirizine to infants and toddlers aged less than 2 years</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with Levocetirizine (including no studies with CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there were no clinically relevant adverse interactions (with antipyrine, pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, glipizide and diazepam). A small decrease in the clearance of cetirizine (16%) was observed in a multiple dose study with theophylline (400 mg once a day); while the disposition of theophylline was not altered by concomitant cetirizine administration.</p><p>In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir was slightly altered (-11%) further to concomitant cetirizine administration.</p><p>The extent of absorption of Levocetirizine is not reduced with food, although the rate of absorption is decreased.</p><p>In sensitive patients the simultaneous administration of cetirizine or Levocetirizine and alcohol or other CNS depressants may have effects on the central nervous system, although it has been shown that the racemate cetirizine does not potentiate the effect of alcohol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For Levocetirizine no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant or lactating women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Comparative clinical trials have revealed no evidence that Levocetirizine at the recommended dose impairs mental alertness, reactivity or the ability to drive.</p><p>Nevertheless, some patients could experience somnolence, fatigue and asthenia under therapy with Levocetirizine. Therefore, patients intending to drive, engage in potentially hazardous activities or operate machinery should take their response to the medicinal product into account</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Clinical studies</p><p>In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the Levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the placebo group. 91.6 % of these adverse drug reactions were mild to moderate.</p><p>In therapeutic trials, the drop out rate due to adverse events was 1.0% (9/935) with Levocetirizine 5 mg and 1.8% (14/771) with placebo.</p><p>Clinical therapeutic trials with Levocetirizine included 935 subjects exposed to the drug at the recommended dose of 5 mg daily. From this pooling, following incidence of adverse drug reactions were reported at rates of 1 % or greater (common: &gt;1/100, &lt;1/10) under Levocetirizine 5 mg or placebo:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Preferred Term</p><p>(WHOART)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(n =771)</p></td><td style="vertical-align:top"><p>Levocetirizine 5 mg</p><p>(n = 935)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>25 (3.2 %)</p></td><td style="vertical-align:top"><p>24 (2.6 %)</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>11 (1.4 %)</p></td><td style="vertical-align:top"><p>49 (5.2 %)</p></td></tr><tr><td style="vertical-align:top"><p>Mouth dry</p></td><td style="vertical-align:top"><p>12 (1.6%)</p></td><td style="vertical-align:top"><p>24 (2.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>9 (1.2 %)</p></td><td style="vertical-align:top"><p>23 (2.5 %)</p></td></tr></tbody></table><p>Further uncommon incidences of adverse reactions (uncommon &gt;1/1000, &lt;1/100) like asthenia or abdominal pain were observed.</p><p>The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia was altogether more common (8.1 %) under Levocetirizine 5 mg than under placebo (3.1%).</p><p>Paediatric population</p><p>In two placebo-controlled studies in paediatric patients aged 6-11 months and aged 1 year to less than 6 years, 159 subjects were exposed to Levocetirizine at the dose of 1.25mg daily for 2 weeks and 1.25mg twice daily respectively. The following incidence of adverse drug reactions was reported at rates of 1% or greater under Levocetirizine or placebo.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>System Organ Class and Preferred Term</p></td><td style="vertical-align:top"><p>Placebo</p><p>(n=83)</p></td><td style="vertical-align:top"><p>Levocetirizine</p><p>(n=159)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3(1.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>1(0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2(1.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Salivary hypersecretion</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Thirst</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hunger</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>2(2.4%)</p></td><td style="vertical-align:top"><p>3(1.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Psychomotor hyperactivity</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disorder</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2(1.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Middle insomnia</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>In children aged 6-12 years double blind placebo controlled studies were performed where 243 children were exposed to 5mg Levocetirizine daily for variable periods ranging from less than 1 week to 13 weeks. The following incidence of adverse drug reactions was reported at rates of 1% or greater under Levocetirizine or placebo.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Preferred Term</p></td><td style="vertical-align:top"><p>Placebo (n=240)</p></td><td style="vertical-align:top"><p>Levocetirizine 5mg (n=243)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>5(2.1%)</p></td><td style="vertical-align:top"><p>2(0.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>1(0.4%)</p></td><td style="vertical-align:top"><p>7(2.9%)</p></td></tr></tbody></table><p>As stated in sections 4.2 and 4.4, please note that even if clinical data presented in this section are available in children aged 6 months to 12 years, we do not have sufficient data to support the administration of the product to infants and toddlers aged less than 2 years.</p><p>Post-marketing experience</p><p>In addition to the adverse reactions reported during clinical studies and listed above, very rare cases of the following adverse drug reactions have been reported in post-marketing experience.</p><p>&bull; Immune system disorders: hypersensitivity including anaphylaxis</p><p>&bull; Psychiatric disorders: aggression, agitation, hallucination, depression</p><p>&bull; Nervous system disorders: convulsion, paraesthesia, dizziness</p><p>&bull; Eyes disorders: visual disturbances, blurred vision</p><p>&bull; Cardiac disorders: palpitations, tachycardia</p><p>&bull; Respiratory, thoracic, and mediastinal disorders: dyspnoea</p><p>&bull; Gastrointestinal disorders: nausea, vomiting</p><p>&bull; Hepatobiliary disorders: hepatitis</p><p>&bull; Renal and urinary disorders: dysuria</p><p>&bull; Skin and subcutaneous tissue disorders: angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria</p><p>&bull; Musculoskeletal, connective tissues, and bone disorders: myalgia</p><p>&bull; Investigations: weight increased, abnormal liver function tests</p><p>Methyl parahydroxybenzoate and propyl parahydroxybenzoate may cause allergic reactions (possibly delayed).</p></td><td>&nbsp;</td></tr></tbody></table><p>To reports any side effect (s):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&bull; Fax: +966-11-205-7662</p><p>&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>&bull; Reporting hotline: 19999</p><p>&bull; E-mail: npc.drug@sfda.gov.sa</p><p>&bull; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a) Symptoms</p><p>Symptoms of overdose may include drowsiness in adults and initially agitation and restlessness, followed by drowsiness in children.</p><p>b) Management of overdoses</p><p>There is no known specific antidote to Levocetirizine.</p><p>Should overdose occur, symptomatic or supportive treatment is recommended. Gastric lavage should be considered following short-term ingestion. Levocetirizine is not effectively removed by haemodialysis</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antihistamine for systemic use, piperazine derivative.</p><p>ATC code: R06A E09.</p><p>Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors.</p><p>Binding studies revealed that Levocetirizine has high affinity for human H1-receptors (Ki = 3.2 nmol/l). Levocetirizine has an affinity 2-fold higher than that of cetirizine (Ki = 6.3 nmol/l). Levocetirizine dissociates from H1-receptors with a half-life of 115 &plusmn; 38 min.</p><p>After single administration, Levocetirizine shows a receptor occupancy of 90% at 4 hours and 57% at 24 hours.</p><p>Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, Levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.</p><p>The pharmacodynamic activity of Levocetirizine has been studied in randomised, controlled trials:</p><p>In a study comparing the effects of Levocetirizine 5mg, desloratadine 5mg, and placebo on histamine-induced wheal and flare, Levocetirizine treatment resulted in significantly decreased wheal and flare formation which was highest in the first 12 hours and lasted for 24 hours, (p&lt;0.001) compared with placebo and desloratadine.</p><p>The onset of action of Levocetirizine 5 mg in controlling pollen-induced symptoms has been observed at 1 hour post drug intake in placebo controlled trials in the model of the allergen challenge chamber.</p><p>In vitro studies (Boyden chambers and cell layers techniques) show that Levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through both dermal and lung cells. A pharmacodynamic experimental study in vivo (skin chamber technique) showed three main inhibitory effects of Levocetirizine 5 mg in the first 6 hours of pollen-induced reaction, compared with placebo in 14 adult patients: inhibition of VCAM-1 release, modulation of vascular permeability and a decrease in eosinophil recruitment.</p><p>The efficacy and safety of Levocetirizine has been demonstrated in several double-blind, placebo controlled, clinical trials performed in adult patients suffering from seasonal allergic rhinitis, perennial allergic rhinitis, or persistent allergic rhinitis. Levocetirizine has been shown to significantly improve symptoms of allergic rhinitis, including nasal obstruction in some studies.</p><p>A 6-month clinical study in 551 adult patients (including 276 Levocetirizine-treated patients) suffering from persistent allergic rhinitis (symptoms present 4 days a week for at least 4 consecutive weeks) and sensitized to house dust mites and grass pollen demonstrated that Levocetirizine 5 mg was clinically and statistically significantly more potent than placebo on the relief from the total symptom score of allergic rhinitis throughout the whole duration of the study, without any tachyphylaxis. During the whole duration of the study, Levocetirizine significantly improved the quality of life of the patients.</p><p>The paediatric safety and efficacy of Levocetirizine tablets has been studied in two placebo controlled clinical trials including patients aged 6 to 12 years and suffering from seasonal and perennial allergic rhinitis, respectively. In both trials, Levocetirizine significantly improved symptoms and increased health-related quality of life.</p><p>In children below the age of 6 years, clinical safety has been established from several short- or long -term therapeutic studies:</p><p>- one clinical trial in which 29 children 2 to 6 years of age with allergic rhinitis were treated with Levocetirizine 1.25 mg twice daily for 4 weeks</p><p>- one clinical trial in which 114 children 1 to 5 years of age with allergic rhinitis or chronic idiopathic urticaria were treated with Levocetirizine 1.25 mg twice daily for 2 weeks</p><p>- one clinical trial in which 45 children 6 to 11 months of age with allergic rhinitis or chronic idiopathic urticaria were treated with Levocetirizine 1.25 mg once daily for 2 weeks</p><p>- one long-term (18 months) clinical trial in 255 Levocetirizine - treated atopic subjects aged 12 to 24 months at inclusion.</p><p>The safety profile was similar to that seen in the short-term studies conducted in children 1 to 5 years of age.</p><p>In a placebo-controlled clinical trial including 166 patients suffering from chronic idiopathic urticaria, 85 patients were treated with placebo and 81 patients with Levocetirizine 5mg once daily over six weeks. Treatment with Levocetirizine resulted in significant decrease in pruritus severity over the first week and over the total treatment period as compared to placebo. Levocetirizine also resulted in a larger improvement of health-related quality of life as assessed by the Dermatology Life Quality Index as compared to placebo.</p><p>Chronic idiopathic urticaria was studied as a model for urticarial conditions. Since histamine release is a causal factor in urticarial diseases, Levocetirizine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria.</p><p>Pharmacokinetic / pharmacodynamic relationship:</p><p>The action on histamine-induced skin reactions is out of phase with the plasma concentrations.</p><p>ECGs did not show relevant effects of Levocetirizine on QT interval</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of Levocetirizine are linear with dose- and time-independent with low inter-subject variability. The pharmacokinetic profile is the same when given as the single enantiomer or when given as cetirizine. No chiral inversion occurs during the process of absorption and elimination.</p><p>Absorption:</p><p>Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 h after dosing. Steady state is achieved after two days. Peak concentrations are typically 270 ng/ml and 308 ng/ml following a single and a repeated 5 mg o.d. dose, respectively. The extent of absorption is dose-independent and is not altered by food, but the peak concentration is reduced and delayed.</p><p>&nbsp;</p><p>&nbsp;</p><p>Distribution:</p><p>No tissue distribution data are available in humans, neither concerning the passage of Levocetirizine through the blood-brain-barrier. In rats and dogs, the highest tissue levels are found in liver and kidneys, the lowest in the CNS compartment.</p><p>In humans, Levocetirizine is 90% bound to plasma proteins. The distribution of Levocetirizine is restrictive, as the volume of distribution is 0.4 l/kg.</p><p>Biotransformation:</p><p>The extent of metabolism of Levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, N- and O- dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by CYP 3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms. Levocetirizine had no effect on the activities of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 at concentrations well above peak concentrations achieved following a 5 mg oral dose.</p><p>Due to its low metabolism and absence of metabolic inhibition potential, the interaction of Levocetirizine with other substances, or vice-versa, is unlikely.</p><p>Elimination:</p><p>The plasma half-life in adults is 7.9 &plusmn; 1.9 hours. The half-life is shorter in small children.</p><p>The mean apparent total body clearance in adults is 0.63 ml/min/kg. The major route of excretion of Levocetirizine and metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via faeces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion.</p><p>Renal impairment:</p><p>The apparent body clearance of Levocetirizine is correlated to the creatinine clearance. It is therefore recommended to adjust the dosing intervals of Levocetirizine, based on creatinine clearance in patients with moderate and severe renal impairment. In anuric end stage renal disease subjects, the total body clearance is decreased by approximately 80% when compared to normal subjects. The amount of Levocetirizine removed during a standard 4-hour hemodialysis procedure was &lt; 10%.</p><p>Paediatric population:</p><p>Data from a paediatric pharmacokinetic study with oral administration of a single dose of 5 mg Levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg show that Cmax and AUC values are about 2-fold greater than that reported in healthy adult subjects in a cross-study comparison. The mean Cmax was 450 ng/mL, occurring at a mean time of 1.2 hours, weight-normalized, total body clearance was 30% greater, and the elimination half-life 24% shorter in this paediatric population than in adults. Dedicated pharmacokinetic studies have not been conducted in paediatric patients younger than 6 years of age. A retrospective population pharmacokinetic analysis was conducted in 324 subjects (181 children 1 to 5 years of age, 18 children 6 to 11 years of age, and 124 adults 18 to 55 years of age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg. Data generated from this analysis indicated that administration of 1.25 mg once daily to children 6 months to 5 years of age is expected to result in plasma concentrations similar to those of adults receiving 5 mg once daily.</p><p>Geriatric Patients:</p><p>Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat oral administration of 30 mg Levocetirizine for 6 days in 9 elderly subjects (65&ndash;74 years of age), the total body clearance was approximately 33% lower compared to that in younger adults. The disposition of racemic cetirizine has been shown to be dependent on renal function rather than on age. This finding would also be applicable for Levocetirizine, as Levocetirizine and cetirizine are both predominantly excreted in urine. Therefore, the Levocetirizine dose should be adjusted in accordance with renal function in elderly patients.</p><p>Gender:</p><p>Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect of gender. The half-life was slightly shorter in women (7.08 &plusmn; 1.72 hr) than in men (8.62 &plusmn; 1.84 hr); however, the body weight-adjusted oral clearance in women (0.67 &plusmn; 0.16 mL/min/kg) appears to be comparable to that in men (0.59 &plusmn; 0.12 mL/min/kg). The same daily doses and dosing intervals are applicable for men and women with normal renal function.</p><p>Race:</p><p>The effect of race on Levocetirizine has not been studied. As Levocetirizine is primarily renally excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic characteristics of Levocetirizine are not expected to be different across races. No race-related differences in the kinetics of racemic cetirizine have been observed.</p><p>Hepatic impairment:</p><p>The pharmacokinetics of Levocetirizine in hepatically impaired subjects have not been tested. Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of the racemic compound cetirizine as a single dose had a 50% increase in half life along with a 40% decrease in clearance compared to healthy subjects</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction, genotoxicity or carcinogenicity</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sorbitol liquid 70 %, Glycerol, Propylene Glycol, Methyl Paraben, Propyl Paraben, Sodium Acetate, Peach Flavor, water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Layal syrup are valid for 2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p><p>Do not use Layal after the bottle has been opened for more than 1 month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber glass bottle with screw cap each packed in A printed carton with a folded pack insert</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Do not use if cap seal is broken</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization Company (JOSWE-medical)
P.O. Box 851831 Amman 11185 Jordan 
E-mail: joswe@go.com.jo

Head office: Sweifyeh.
Tel: +962 6 5859765 - + 962 6 5812748
Fax: +962 6 5814526
Fax: +962 6 5728326

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December, 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>